TACTIC-2 marks first in-human use of TAC-T cell therapy Phase 1/2 clinical trial will evaluate TAC01-HER2, Triumvira’s lead candidate, in patients with HER2-overexpressing solid tumors First patient dosed at MD Anderson Cancer Center in Houston, Texas AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”) today announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. Triumvira, a clinical-stage company, is developing novel, targeted autologous, and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors. The company’s proprietary T cell Antigen Coupler (TAC) platform technology activates natural T cell functions differently from other cell therapies such as Chimeric Antigen Receptor T cell (CAR-T) and engineered T cell receptor therapies.
